Freenome Files 8‑K Amendment, Provides Q2 2026 MD&A

What Happened

• On August 13, 2026 Freenome, Inc. (New Freenome) filed Amendment No. 1 to its Form 8‑K that incorporates Management’s Discussion and Analysis (MD&A) of financial condition and results of operations for the three‑ and six‑month periods ended June 30, 2026 and June 30, 2025 as Exhibit 99.2.
• The amendment references Item 2.01 and Item 9.01 of Form 8‑K and incorporates the MD&A by reference into the filing.

Key Details

• Filing date: August 13, 2026 (Amendment No. 1 to previously filed 8‑K).
• MD&A period covered: three- and six-month periods ended June 30, 2026 and June 30, 2025 (Exhibit 99.2).
• Regulatory note: New Freenome is a "smaller reporting company" and therefore is not required to provide Quantitative and Qualitative Disclosures about Market Risk.
• The amendment incorporates exhibits and references financial statement/exhibit information under Item 9.01.

Why It Matters

• The MD&A (Exhibit 99.2) contains management’s discussion of Freenome’s quarterly results and financial condition for Q2 2026 and the comparable period in 2025; investors should review that exhibit for details on revenue, expenses, cash flow and operational drivers.
• Because Freenome qualifies as a smaller reporting company, the filing omits formal market‑risk disclosures (e.g., interest‑rate, currency or other market risks) that larger filers often provide; investors seeking those analyses should look to other filings or company disclosures.
• This amendment formalizes the inclusion of MD&A into the public record—use Exhibit 99.2 and related filings for the full quantitative details before making investment decisions.